UNIQURE NV's ticker is QURE and the CUSIP is N90064101. A total of 101 filers reported holding UNIQURE NV in Q3 2018. The put-call ratio across all filers is 0.04 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2021 | $2,891,000 | -14.7% | 85,819 | -8.5% | 0.00% | -33.3% |
| Q4 2020 | $3,388,000 | +7.9% | 93,760 | +9.9% | 0.00% | 0.0% |
| Q3 2020 | $3,141,000 | -16.2% | 85,295 | +2.5% | 0.00% | -25.0% |
| Q2 2020 | $3,749,000 | +2.1% | 83,195 | +7.5% | 0.00% | 0.0% |
| Q1 2020 | $3,673,000 | -55.3% | 77,400 | -32.5% | 0.00% | -42.9% |
| Q4 2019 | $8,219,000 | +157.6% | 114,693 | +41.5% | 0.01% | +133.3% |
| Q3 2019 | $3,190,000 | -12.5% | 81,047 | +73.8% | 0.00% | -25.0% |
| Q2 2019 | $3,645,000 | +28.2% | 46,635 | -2.2% | 0.00% | 0.0% |
| Q1 2019 | $2,844,000 | +105.2% | 47,686 | -0.8% | 0.00% | +100.0% |
| Q4 2018 | $1,386,000 | -24.0% | 48,086 | -4.0% | 0.00% | 0.0% |
| Q3 2018 | $1,823,000 | +69.6% | 50,086 | +76.2% | 0.00% | +100.0% |
| Q2 2018 | $1,075,000 | +223.8% | 28,427 | +101.3% | 0.00% | – |
| Q1 2018 | $332,000 | – | 14,120 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| MPM BioImpact LLC | 939,966 | $21,309,029 | 5.53% |
| Aquilo Capital Management, LLC | 624,854 | $14,165,440 | 5.32% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 631,500 | $14,297,160 | 4.42% |
| Nantahala Capital Management | 2,700,239 | $61,214,418 | 3.97% |
| Integral Health Asset Management, LLC | 550,000 | $12,468,500 | 2.62% |
| Privium Fund Management B.V. | 301,298 | $6,830,426 | 2.59% |
| 683 Capital Management, LLC | 1,145,000 | $25,957,150 | 2.20% |
| PFM Health Sciences, LP | 2,302,314 | $52,193,458 | 1.87% |
| Nantahala Capital Management | 1,187,700 | $26,925,159 | 1.74% |
| Jetstream Capital LLC | 30,000 | $680,100 | 1.44% |